FI922719A0 - ANVAENDNING AV ANTIKOAGULANT SOM DIAGNOSMEDEL. - Google Patents

ANVAENDNING AV ANTIKOAGULANT SOM DIAGNOSMEDEL.

Info

Publication number
FI922719A0
FI922719A0 FI922719A FI922719A FI922719A0 FI 922719 A0 FI922719 A0 FI 922719A0 FI 922719 A FI922719 A FI 922719A FI 922719 A FI922719 A FI 922719A FI 922719 A0 FI922719 A0 FI 922719A0
Authority
FI
Finland
Prior art keywords
esp
anticoagulant
diagnosmedel
antikoagulant
anvaendning
Prior art date
Application number
FI922719A
Other languages
Finnish (fi)
Other versions
FI107586B (en
Inventor
Christiaan Reutelingsperger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6396455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI922719(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of FI922719A0 publication Critical patent/FI922719A0/en
Application granted granted Critical
Publication of FI107586B publication Critical patent/FI107586B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Dental Preparations (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticoagulant polypeptides (I) of the annexin family, labelled with a detectable marker are new. Also new are compsns. contg. (I) plus auxiliaries. (I) is esp. VAC (vascular anticoagulant protein) and suitable markers include fluorescein isothiocyanate, a radioisotope (esp. 131- or 125-iodine) or a paramagnetic contrast agent. (I), which can be administered intravenously or intraarterially, are formulated with physiological saline, 'Tween 80', arginine and/or phosphate buffer. The compsn. may also include an anticoagulant, esp. heparin, which has no effect on plasma Ca concn.
FI922719A 1989-12-27 1992-06-12 Use of anticoagulant as diagnostic agent FI107586B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3942988 1989-12-27
DE3942988 1989-12-27
EP9002257 1990-12-19
PCT/EP1990/002257 WO1991009628A1 (en) 1989-12-27 1990-12-19 Use of an anticoagulant as a diagnostic agent

Publications (2)

Publication Number Publication Date
FI922719A0 true FI922719A0 (en) 1992-06-12
FI107586B FI107586B (en) 2001-09-14

Family

ID=6396455

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922719A FI107586B (en) 1989-12-27 1992-06-12 Use of anticoagulant as diagnostic agent

Country Status (15)

Country Link
EP (2) EP0806670B1 (en)
JP (1) JP3135261B2 (en)
KR (1) KR0181520B1 (en)
AT (2) ATE164083T1 (en)
AU (1) AU642202B2 (en)
CA (1) CA2070647C (en)
DE (3) DE4040817A1 (en)
ES (1) ES2113372T3 (en)
FI (1) FI107586B (en)
HU (2) HUT61491A (en)
NO (1) NO305276B1 (en)
NZ (1) NZ236620A (en)
PT (1) PT96385B (en)
WO (1) WO1991009628A1 (en)
ZA (1) ZA9010319B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
ATE210464T1 (en) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA CONJUGATES AND THEIR USE IN PRETARGETING PROCEDURES
WO1995014788A1 (en) * 1993-11-24 1995-06-01 University Of Washington Blood coagulation retardants and devices
DE69530375T2 (en) * 1994-01-24 2004-02-05 Neorx Corp., Seattle RADIOACTIVE-MARKED ANNEXINE
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
DE69518319T2 (en) * 1994-03-16 2000-12-14 Mallinckrodt, Inc. USE OF SURFACE-ACTIVE SUBSTANCES FOR THE STABILIZATION OF PEPTIDES AND PROTEINS FOR RADIOPHARMACEUTICAL USE
JP2824155B2 (en) * 1994-04-11 1998-11-11 ネクシンズ・リサーチ・ベー・ブイ Method for detecting and / or optionally quantifying and / or separating apoptotic cells in or from a sample
ATE240749T1 (en) * 1994-06-16 2003-06-15 Neorx Corp RADIOACTIVE LABELED ANNEXIN-GALACTOSE CONJUGATES
JPH10504534A (en) * 1994-06-16 1998-05-06 ネオルクス コーポレイション Radiolabeled annexin-galactose conjugate
CA2206274C (en) * 1994-12-07 2009-06-30 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
EP1486509A3 (en) * 1994-12-07 2005-03-23 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
FR2736197B1 (en) * 1995-06-29 1997-09-12 Univ Paris Curie MAGNETIC NANOPARTICLES COUPLED WITH ANNEXIN AND THEIR USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
PT87083B (en) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int A PROCESS FOR THE PREPARATION OF A VASCULAR ANTICOAGULANT PROTEIN, OF DNA THAT CODIFIES FOR THIS PROTEIN AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING IT
DE3810331A1 (en) * 1988-03-26 1989-10-05 Boehringer Ingelheim Int Monoclonal VAC antibodies

Also Published As

Publication number Publication date
HUT61491A (en) 1993-01-28
KR920703121A (en) 1992-12-17
PT96385A (en) 1991-10-31
NO305276B1 (en) 1999-05-03
ATE164083T1 (en) 1998-04-15
JPH05502877A (en) 1993-05-20
AU7071191A (en) 1991-07-24
JP3135261B2 (en) 2001-02-13
PT96385B (en) 1998-06-30
WO1991009628A1 (en) 1991-07-11
CA2070647C (en) 2001-04-10
AU642202B2 (en) 1993-10-14
KR0181520B1 (en) 1999-05-01
EP0806670A3 (en) 1997-12-10
NO922528D0 (en) 1992-06-26
HU209650B (en) 1994-09-28
EP0806670A2 (en) 1997-11-12
FI107586B (en) 2001-09-14
HU9202149D0 (en) 1992-10-28
EP0509026A1 (en) 1992-10-21
EP0806670B1 (en) 2009-04-22
ATE429644T1 (en) 2009-05-15
DE59010815D1 (en) 1998-04-23
ES2113372T3 (en) 1998-05-01
NZ236620A (en) 1997-03-24
NO922528L (en) 1992-08-26
CA2070647A1 (en) 1991-06-28
ZA9010319B (en) 1992-08-26
DE4040817A1 (en) 1991-07-04
EP0509026B1 (en) 1998-03-18
DE59010946D1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
FI922719A0 (en) ANVAENDNING AV ANTIKOAGULANT SOM DIAGNOSMEDEL.
ATE123301T1 (en) GENETICALLY PRODUCED APROTININE HOMOLOGUE.
SE8000469L (en) TISSUE BINDING AND PROCEDURE FOR ITS MANUFACTURING AND USING THE BINDING AGENT
ATE199016T1 (en) TYPE-IV DIPEPTIDYL-AMINOPEPTIDASE INHIBITORS
ES2113532T3 (en) DEVICE FOR THE DETERMINATION OF THE FILLING LEVEL OF A BLOOD CIRCULATORY SYSTEM.
NO964007L (en) Combinations of thrombolytically active proteins and anticoagulants and their use
ATE125269T1 (en) RADIOM LABELED PEPTIDES WITH ANTICOAGULATE EFFECT.
ES2151517T3 (en) EFFECTS OF ACTINA FILAMENTS ON THE STRUCTURE AND LISIS OF FIBRINE COAGULES.
ES2076544T3 (en) PROCEDURE FOR THE QUICK SELECTION OF EFFECTIVE SECRETION VECTORS.
DK226889D0 (en) ALCOHOLPEPTIDE DERIVATIVES AND ITS USE TO REDUCE BLOOD COAGULATION
ES2078289T3 (en) AGENT TO IMPROVE THE ANEXINES RECOVERY.
BG97199A (en) ANTICOAGULANT PREPARATION
DE69023459D1 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin derivatives.
FR2665769B1 (en) DETERMINATION OF THROMBOPENIA ESPECIALLY INDUCED BY HEPARIN BY MEANS OF THE PLATELET FACTOR 4.
Al-Mondhiry et al. Platelet and fibrinogen survival in calves implanted with artificial heart and ventricular assist device-correlation with autopsy findings
FI885025A (en) KOAGULATIONSHAEMMANDE PROTEIN PP4-X, DESS FRAMSTAELLNING OCH ANVAENDNING.
Ramrakhyani et al. Hepatitis B viral markers and liver disease in haemophiliacs: A study in an Indian population
Eckhardt 20. NOSSEL. HC. YOUNGER. L R.. WILNER. GD, PROCUPEZ. T.. CANFIELD. R. E., BUTLER. VP: Radioimmunassay of human fibrinopeptide A. Proc. Natl. Acad. Sei. USA 68. 2350 (1971). 21. NOSSEL HL YUDELMANN. J., CANFIELD. RE, BUTLER. VP. SPANON-DIS. K., WILNER. GD, QURESHI, GD: Measurement of fibrinopeptide A in human
Hee Basic Principles of Nursing Care
TAKETOMI et al. The ultrastructural localization of platelet factor 4 and fibronectin in human platelets
Shin et al. Effect of Cycloheximide on the Specific Activity of Na+-K+-activated Adenosine Triphosphatase in Human Neonatal Erythrocytes
DE69131248D1 (en) INHIBITION OF SEPARATION OF SODIUM BY NA-K-ATPASE
Kirschstein et al. 18 Restenosis after percutaneous transluminal coronary angioplasty: Evaluation of the fibrinolytic system
IT8718801V0 (en) UNDERWEAR PANTS OF THE DISPOSABLE TYPE NIKY.
ES2039304B1 (en) NON-OBSTRUCTING VASCULAR CATHETER OF THE BLOOD FLOW.